Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions

Thirlwell, K. L., Colligan, D., Mountford, J. C., Samuel, K., Bailey, L., Cuesta-Gomez, N., Hewit, K. D., Kelly, C. J., West, C. C., McGowan, N. W., Casey, J. J., Graham, G. J., Turner, M. L., Forbes, S. and Campbell, J. D.  Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions.  Cytotherapy. 2020; 22(12), 762-771.  doi: 10.1016/j.jcyt.2020.07.010

Date

BioLife Solutions Symbol

This website uses cookies to ensure you get the best experience on our website.